166 related articles for article (PubMed ID: 11313935)
1. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
[TBL] [Abstract][Full Text] [Related]
2. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
3. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
4. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
5. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.
He Q; Dong J; Zhen H; Ying Y; Zhang J; Li Q; Li B; Zhou Y
Leuk Res; 2011 Aug; 35(8):1074-9. PubMed ID: 21163528
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
8. The bcr-abl gene in chronic myelogenous leukaemia.
Sawyers CL
Cancer Surv; 1992; 15():37-51. PubMed ID: 1451113
[TBL] [Abstract][Full Text] [Related]
9. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
11. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
13. Exon-skipping in BCR/ABL is induced by ABL exon 2.
Lichty BD; Kamel-Reid S
Biochem J; 2000 May; 348 Pt 1(Pt 1):63-9. PubMed ID: 10794714
[TBL] [Abstract][Full Text] [Related]
14. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
15. Bcr/Abl associated leukemogenesis in bcr null mutant mice.
Voncken JW; Kaartinen V; Groffen J; Heisterkamp N
Oncogene; 1998 Apr; 16(15):2029-32. PubMed ID: 9591787
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
17. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis.
Skorski T; Nieborowska-Skorska M; Szczylik C; Kanakaraj P; Perrotti D; Zon G; Gewirtz A; Perussia B; Calabretta B
Cancer Res; 1995 Jun; 55(11):2275-8. PubMed ID: 7757976
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
19. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; GodÃnez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
20. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
